Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 332 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mitochondrial Metabolism Disorders Clear all

Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2), Mitochondrial Trifunctional Protein Deficiency, Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency, Glycogen Storage Disorders, Pyruvate Carboxylase Deficiency Disease, ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of, Barth Syndrome
Interventions: triheptanoin; Drug
Lead sponsor: Jerry Vockley, MD, PhD; Other
Eligibility: 1 Month and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
Interventions: NucleomaxX, Tenofovir Disoproxil Fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Francisco, California • Washington D.C., District of Columbia

Conditions: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions: zagociguat 15mg, zagociguat 30mg, Placebo; Drug
Lead sponsor: Tisento Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Zidovudine, Didanosine, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Irvine, California • Washington D.C., District of Columbia • Galveston, Texas

Conditions: Type 2 Diabetes
Interventions: Maximal ATP Production (ATPmax), Exercise Testing (VO2max), Muscle Biopsy, Adipose Tissue Biopsy, Hyperinsulinemic euglycemic clamp, PET imaging; Other · Procedure
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 30 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Friedreich Ataxia
Interventions: Elamipretide; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Friedreich's Ataxia
Interventions: GV101, Placebo; Drug
Lead sponsor: Graviton Bioscience Corporation; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Cytomegalovirus Infections
Interventions: Not listed
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Carboplatin, Durvalumab, Paclitaxel, Papaverine, Radiation Therapy, Pemetrexed, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging of the Brain with and without Contrast, Biospecimen Collection; Drug · Biological · Radiation + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Duarte, California • Columbus, Ohio

Conditions: Spinocerebellar Ataxia - All Sub-types, Friedreich's Ataxia
Interventions: Ataxia rating scale; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: San Diego, California • San Francisco, California • San Mateo, California + 14 more

Conditions: Friedreich's Ataxia (FA)
Interventions: SGT-212; Drug
Lead sponsor: Solid Biosciences Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Los Angeles, California • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
Interventions: Metformin; Drug
Lead sponsor: Woodinville Psychiatric Associates; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Woodinville, Washington

Conditions: Brain Neoplasm, Neoplasm Metastasis
Interventions: Cytovene (Ganciclovir Sodium), G1TKSVNa.53 Producer Cell Line; Drug · Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mitochondrial Diseases
Interventions: Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence; Diagnostic Test
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 7 Years to 75 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Obese
Interventions: Lipid infusion and muscle biopsies; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Spinal Muscular Atrophy Type 3, Mitochondrial Myopathy
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 8 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy
Interventions: Mutation analysis; Genetic
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 0 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Zidovudine, Sargramostim, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Insulin Resistance, Diabetes
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, Obesity
Interventions: Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies; Behavioral · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 59 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Search by objective public record fields.

Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism

Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults

A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir

A Phase 2b Study of Zagociguat in Patients With MELAS

Longitudinal Study of Mitochondrial Hepatopathies

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes

FRDA Investigator Initiated Study (IIS) With Elamipretide

GV101 for Friedreich's Ataxia (FA) Treatment

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

Heart Rate Variability in Response to Metformin Challenge

Gene Therapy for the Treatment of Brain Tumors

CrCest Study in Primary Mitochondrial Disease

PGC-1 and Mitochondrial Dysfunction in Diabetes

Oxidative Capacity and Exercise Tolerance in Ambulatory SMA

Natural History Study of SLC25A46 Mutation-related Mitochondriopathy

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

Pilot Study of Mitochondrial Biology in Human Platelets

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes